A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Phase 1 Completed 9 enrolled AbbVie

NaSingle-groupOpen-labelTreatment

Summary

An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.

Timeline

Start: 2017-11-06
Primary completion: 2019-03-04
Completion: 2019-03-04

Publications

Fujiwara Y, Kenmotsu H, Yamamoto N, Shimizu T, Yonemori K, Ocampo C, Parikh A, Okubo S, Fukasawa K, Murakami H. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Med. 2021 Apr;10(7):2350-2358. doi: 10.1002/cam4.3815. Epub 2021 Mar 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telisotuzumab Vedotin	Monoclonal antibody	2.4 mg/kg	Intravenous
Subject	Telisotuzumab Vedotin	Monoclonal antibody	2.7 mg/kg	Intravenous

Indications

No indication recorded.